Combination therapy vs. higher dose ustekinumab for Crohn's
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether a combination of two drugs (upadacitinib and ustekinumab) works better than a higher dose of ustekinumab alone for people with active Crohn's disease that hasn't responded well to previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have active Crohn's disease that is not well controlled.
- You have already tried a TNF inhibitor (like adalimumab or infliximab) and it didn't work well enough.
- You have been on a standard dose of ustekinumab (Stelara) for at least 16 weeks, but it hasn't fully controlled your Crohn's.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment for people with Crohn's disease who have lost response to ustekinumab (Stelara). It aims to see if a different dosing or additional treatment can help regain control of symptoms.
This study follows adults with Crohn’s disease or ulcerative colitis to compare the long-term safety of ustekinumab against other biologic medicines. It may help show how safe these treatments are over time, using medical records.
This Phase 1 study uses a special camera to track how ustekinumab (a common biologic medicine) spreads in inflamed tissue. It aims to help researchers understand where the drug goes in Crohn’s disease and psoriasis, especially when standard treatments haven’t worked.
This study tailors ustekinumab (Stelara) treatment specifically for people with fistulizing Crohn's disease around the anus. It aims to find the best way to use this medicine to improve symptoms like pain and drainage from fistulas.
Researchers want to see if taking two medications together (upadacitinib and vedolizumab) works better than taking just upadacitinib alone for people with moderate to severe ulcerative colitis. This is a real-world study, meaning it looks at patients being treated in normal medical practice.
This trial tests if adding a low dose of a newer pill (upadacitinib) to your current TNF inhibitor (TNFi) works better than increasing the dose of your TNFi alone. It is for people with Crohn's disease who have had some improvement on their TNFi but still have active disease.
Hear when a new Crohn Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.